Life
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.
editorial-staff 5 days ago